PDSB Stock Overview
A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PDS Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.95 |
| 52 Week High | US$10.22 |
| 52 Week Low | US$2.59 |
| Beta | 1.75 |
| 1 Month Change | -18.28% |
| 3 Month Change | -55.24% |
| 1 Year Change | -68.68% |
| 3 Year Change | -76.92% |
| 5 Year Change | -52.80% |
| Change since IPO | -65.33% |
Recent News & Updates
Recent updates
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Jan 13PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101
Feb 03PDS Biotechnology gives new CFO ~202K stock grant
Jan 06PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer
Nov 10Shareholder Returns
| PDSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.2% | -1.2% | -1.2% |
| 1Y | -68.7% | 4.7% | 21.5% |
Return vs Industry: PDSB underperformed the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: PDSB underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| PDSB volatility | |
|---|---|
| PDSB Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PDSB's share price has been volatile over the past 3 months.
Volatility Over Time: PDSB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 25 | Frank Bedu-Addo | www.pdsbiotech.com |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers.
PDS Biotechnology Corporation Fundamentals Summary
| PDSB fundamental statistics | |
|---|---|
| Market cap | US$108.20m |
| Earnings (TTM) | -US$43.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs PDSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PDSB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.89m |
| Earnings | -US$43.89m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 64.4% |
How did PDSB perform over the long term?
See historical performance and comparison